- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
VIDEO: Margaret Powers, PhD, RD, CDE, Discusses the Effect Genetic Testing Has on Behavioral Change
Dr. Margaret Powers says that currently genetic testing does not motivate behavior change and weight loss in diabetes care. Patients who did not receive the test did just as well with behavior changes as patients who knew they were high risk through genetic testing.
Dr. Margaret Powers says that currently genetic testing does not motivate behavior change and weight loss in diabetes care. Patients who did not receive the test did just as well with behavior changes as patients who knew they were high risk through genetic testing.
Powers did go on to say that, in the study she refers to, patients who were predisposed to diabetes only had a 17% to 18% risk. She goes on to say that more research needs to be completed in order to determine what might better motivate patients. For instance, the advancement of genetic testing could help determine if a patient is at an even higher risk of diabetes (>17%), in which case, posits Powers, they might become more motivated to change their behavior.
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Targeted Treatment May Improve Outcomes in IDH1-Mutated MDS
January 13th 2025A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that IDH1-targeted treatment may improve survival among patients with myelodysplastic syndromes (MDS) with the mutation.
Read More
